

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

31 May 2026

### The effect of cerebrolysin versus placebo on improvement of patients with acute ischemic stroke: a double blinded randomized clinical trial

#### Protocol summary

##### Summary

**Objectives:** To assess the effect of cerebrolysin versus placebo on improvement of patients with acute ischemic stroke. **Design:** A double blinded randomized clinical trial. **Setting and conduct:** All eligible patients with acute ischemic stroke who will refer to clinic of Farshchian Hospital will be enrolled in to the trial. **Inclusion criteria:** (a) having ischemic stroke; (b) age of 40 to 85 years; (c) referring the patient within less than 24 hours after stroke. **Exclusion criteria:** (a) being in coma; (b) having systolic blood pressure above 240 mmHg or diastolic blood pressure above 120 mmHg; (c) history of myocardial infarction or heart failure; (d) history of renal failure; (e) history of liver failure; (f) having severe dementia. **Intervention:** Routine treatment of ischemic stroke plus intravenous infusion of cerebrolysin 10 ml in 100 ml normal saline daily for 7 days. **Control:** Routine treatment of ischemic stroke plus intravenous infusion of 100 ml normal saline alone daily for 7 days. **Primary outcome:** measuring motor function using Canadian Stroke Scale before intervention and 3 and 7 days after intervention. **Secondary outcome:** (a) measuring motor function using Madified Ranking Scale one month after intervention; (b) measuring motor function using Bartel Index one month after intervention.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201406169014N36**  
Registration date: **2014-06-23, 1393/04/02**  
Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2014-06-23, 1393/04/02

#### Registrant information

##### Name

Jalal Poorolajal

##### Name of organization / entity

Department of Epidemiology & Biostatistics Hamadan  
University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 81 1838 0090

##### Email address

poorolajal@umsha.ac.ir

#### Recruitment status

##### Recruitment complete

#### Funding source

Vice-chancellor for Research the Technology, Hamadan  
University of Medical Sciences

#### Expected recruitment start date

2013-07-23, 1392/05/01

#### Expected recruitment end date

2014-06-21, 1393/03/31

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### Scientific title

The effect of cerebrolysin versus placebo on improvement of patients with acute ischemic stroke: a double blinded randomized clinical trial

#### Public title

The effect of cerebrolysin versus placebo on improvement of patients with acute ischemic stroke

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

Inclusion criteria: (a) having ischemic stroke; (b) age of

40 to 85 years; (c) referring the patient within less than 24 hours after stroke. Exclusion criteria: (a) being in coma; (b) having systolic blood pressure above 240 mmHg or diastolic blood pressure above 120 mmHg; (c) history of myocardial infarction or heart failure; (d) history of renal failure; (e) history of liver failure; (f) having severe dementia.

**Age**

From **40 years** old to **85 years** old

**Gender**

Both

**Phase**

2

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **122**

**Randomization (investigator's opinion)**

Randomized

**Randomization description****Blinding (investigator's opinion)**

Double blinded

**Blinding description****Placebo**

Used

**Assignment**

Parallel

**Other design features**

Randomization: A systematic random allocation method is used so that the patients who referred to the first specialist were assigned to the intervention group and the patients who referred to the second specialist were assigned to the control group. Blinding: All patients received the same intravenous treatment with different context. Thus they were unaware of the type of intervention. In addition, the physician who examined the patients was not aware of the intervention. Therefore, the trial was run as double blinded.

**Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Research Ethic Committee of Hamadan University of Medical Sciences

**Street address**

Vice-chancellor of Research the Technology,  
Hamadan University of Medical Sciences, Shahid Fahmideh Ave

**City**

Hamadan

**Postal code**

6517838695

**Approval date**

2014-05-17, 1393/02/27

**Ethics committee reference number**

P/16/35/9/705

**Health conditions studied****1****Description of health condition studied**

Ischemic stroke

**ICD-10 code**

I63

**ICD-10 code description**

cerebral infarction

**Primary outcomes****1****Description**

measuring motor function

**Timepoint**

before intervention and 3 and 7 days after intervention

**Method of measurement**

using Canadian Stroke Scale

**Secondary outcomes****1****Description**

measuring motor function

**Timepoint**

one month after intervention

**Method of measurement**

using Madified Ranking Scale

**2****Description**

measuring motor function

**Timepoint**

one month after intervention

**Method of measurement**

using Bartel Index

**Intervention groups****1****Description**

Routine treatment of ischemic stroke plus intravenous infusion of cerebrolysin 10 ml in 100 ml normal saline daily for 7 days

**Category**

Treatment - Drugs

**2****Description**

Routine treatment of ischemic stroke plus intravenous infusion of 100 ml normal saline alone daily for 7 days.

**Category**

Placebo

## Recruitment centers

1

### Recruitment center

**Name of recruitment center**

Farshchian Hospital

**Full name of responsible person**

Sajedeh Nazari

**Street address**

Farshchian Hospital, Mirzadeh Eshghi Ave.

**City**

Hamadan

## Sponsors / Funding sources

1

### Sponsor

**Name of organization / entity**

Vice-chancellor for Research the Technology,  
Hamadan University of Medical Sciences

**Full name of responsible person**

Dr Saeid Bashirian

**Street address**

Hamadan University of Medical Sciences, Shahid  
Fahmideh Ave

**City**

Hamadan

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice-chancellor for Research the Technology, Hamadan  
University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Farshchian Hospital

**Full name of responsible person**

Sajedeh Nazari

**Position**

Medical Student

**Other areas of specialty/work**

**Street address**

Farshchian Hospital, Mirzadeh Eshghi Ave.

**City**

Hamadan

**Postal code**

**Phone**

+98 81 3264 0021

**Fax**

**Email**

sajed\_nazari@yahoo.com

**Web page address**

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Farshchian Hospital

**Full name of responsible person**

Dr Mehrdokht Mazdeh

**Position**

Neurologist

**Other areas of specialty/work**

**Street address**

Farshchian Hospital, Mirzadeh Eshghi Ave.

**City**

Hamadan

**Postal code**

**Phone**

+98 81 3264 0021

**Fax**

**Email**

mehrdokhtmazdeh@yahoo.com

**Web page address**

## Person responsible for updating data

### Contact

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*